Posted by AGORACOM-JC
at 4:19 PM on Thursday, March 10th, 2022
To understand Star Navigation $SNA you first have to understand the problem they are solving.
At any given time 200-300 planes can be off the grid when flying and no one knows where they are. In an era in which GPS can easily track dogs, trains and automobiles, it’s hard to imagine that airplane tracking systems are not the strongest of all.
The Malaysian Air Flight 370 and Air France 447 disasters showed the world the weakness in plane monitoring systems … and the strong need for a real solution.
ENTER STAR NAVIGATION SYSTEMS
$SNA is a Flight Sciences Company that bridges the gap between flight experience and flight safety in real-time. In layman terms, that means the Company’s technology provides a continuous connection between planes and the ground … and the result is more than just tracking:
● Real-Time Aircraft Health and Engine Condition Monitoring
● Fuel Management System
● Fleet Management … and more
The Company’s flagship product is the STAR Airborne Data Service (STAR-ADS) which is powered by the patented STAR In-Flight Safety Monitoring System (STAR-ISMS).
GOING TO MARKET WITH FLIGHTPATH – A LEADING PROVIDER TO GLOBAL AIRLINE INDUSTRY SERVING 160+ OPERATORS IN 60+ COUNTRIES
Founded in 2003, FlightPath International is a leading provider of Training and Operational Support services for the commercial airline industry worldwide. FlightPath offers Technical, Pilot, Multi-Crew Pilot Licensing, Cabin and Dispatcher training, with aircraft types that include Airbus, Boeing, Bombardier, De Havilland, and Embraer; serving over 160 Operators in over 60 Countries. Over the past 18 years FPI has gained a reputation for providing the highest standard of Original Equipment Manufacturer (“OEM”) training and customer service.
KENYAN CONFERENCE ATTENDEES REPRESENTED OVER 100 AIRPLANES
Together $SNA and FlightPath hosted an invitation only conference in Kenya for small to mid-sized airlines that represented over 100 airplanes – and if this video is any indication given the partners enthusiasm – it appears to have been a great success with orders expected to be flowing in the coming months.
Sit back and watch this powerful AGORACOM Exclusive with Star Navigation Systems!
Posted by AGORACOM-JC
at 5:44 PM on Monday, February 21st, 2022
To understand Star Navigation $SNA you first have to understand the problem they are solving.
At any given time 200-300 planes can be off the grid when flying and no one knows where they are. In an era in which GPS can easily track dogs, trains and automobiles, it’s hard to imagine that airplane tracking systems are not the strongest of all.
The Malaysian Air Flight 370 and Air France 447 disasters showed the world the weakness in plane monitoring systems … and the strong need for a real solution.
ENTER STAR NAVIGATION SYSTEMS
$SNA is a Flight Sciences Company that bridges the gap between flight experience and flight safety in real-time. In layman terms, that means the Company’s technology provides a continuous connection between planes and the ground … and the result is more than just tracking:
● Real-Time Aircraft Health and Engine Condition Monitoring
● Fuel Management System
● Fleet Management … and more
The Company’s flagship product is the STAR Airborne Data Service (STAR-ADS) which is powered by the patented STAR In-Flight Safety Monitoring System (STAR-ISMS).
Every two years, high-level government and military delegations, as well as senior corporate executives around the world attend the Singapore Airshow. As Asia’s largest Airshow, it is the place to be for leading aerospace companies and budding players eager to make their mark in the international aerospace and defense market.
Building on the Company’s progress at the Dubai Airshow, Star Navigation went into the Singapore Airshow with momentum and confidence – and if this interview is any indication, it appears that shareholders can expect meaningful sales results in 2022.
Sit back and watch this powerful AGORACOM Exclusive with Star Navigation Systems!
Posted by AGORACOM-JC
at 5:46 PM on Wednesday, September 29th, 2021
“I was blown away by FOBI “ ($KO CEO Daniel Petrov)
“Kiaro has built an amazing tech driven cannabis retail business” ($FOBI CEO Rob Anson)
If you’re a shareholder of one of these companies, here is what you need to know about each that makes this technology partnership so powerful:
KIARO is one of Canada’s largest retailers of cannabis, with 16 locations and forecasted annual revenue of $42.7 million from these locations, at a gross profit of $13.7M with further growth anticipated.
FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space. From that core technology they have built a technology stack on top of it that is second to none.
More than just talk, FOBI has completes Integrations with Lightspeed and Shopify to provide real-time Point of Sale data analytics. Moreover, they recently announced another $250.000 Data Consulting Agreement with Azincourt Energy
Posted by AGORACOM-JC
at 4:54 PM on Friday, July 16th, 2021
Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:
If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.
Posted by AGORACOM-JC
at 4:06 PM on Monday, July 12th, 2021
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada.
This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.
We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.
Posted by AGORACOM-JC
at 12:18 PM on Wednesday, June 23rd, 2021
Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
Strong psychedelic drug development pipeline targeting Addiction.
First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
Multiple scalable revenue streams across drug development and clinical delivery.
Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.
“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”
The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.
Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.
A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.
About Awakn Life Sciences
Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Investor Enquiries: KCSA Strategic Communications Valter Pinto / Tim Regan Phone: +1 (212) 896-1254 [email protected]
Media Enquiries: America and Canada: KCSA Strategic Communications Anne Donohoe [email protected]
Rest of World: ROAD Communications Paul Jarman / Anna Ramsey [email protected]
Posted by AGORACOM-JC
at 12:14 PM on Wednesday, June 23rd, 2021
To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.
Awakn has a dual strategic focus:
Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.
Notable Highlights include:
Strategic focus on better treating Addiction with psychedelics.
World leading team focused on psychedelic drug and therapy research.
Strong drug and therapy development pipeline, specifically targeting Addiction.
Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery
Closed $8.3M June 8
BRAND NEW LISTING … commencing trading on NEO
Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.
Posted by AGORACOM-JC
at 7:22 PM on Wednesday, May 12th, 2021
PyroGenesis is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world.
One of those applications is ultra high-tech 3D printing powders that earned the company multiple nominations for “Materials Company of the Year” at the 3D Printing Industry Awards as recently as 2019.
These 2 quotes tell you everything you need to know
“It is very exciting to know that we are now going to be delivering powders to very discerning and distinguished clients.
With the advantages of the NexGen™ powder production line, we believe it is only a matter of time given the major top tier aerospace companies and OEMs are already awaiting powders from this new state-of-the-art production line.”
“The next step is to complete the qualification processes and secure large long-term contracts, thereby providing PyroGenesis with recurring revenues for years to come.”
Watch our great interview with CEO Peter Pascali .
